Agios Pharmaceuticals Inc (0HB0.L)

Healthcare | Medical Pharmaceuticals
Income Statement (Quarterly) 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Revenue 12,880,000 12,455,000 8,726,000 10,730,000
Cost of Revenue 1,679,000 2,961,000 1,085,000 1,260,000
Gross Profit 11,201,000 9,494,000 7,641,000 9,470,000
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 41,274,000 45,869,000 41,527,000 51,697,000
Operating Expenses 128,070,000 136,550,000 114,270,000 134,507,000
Operating Income -116,869,000 -127,056,000 -106,629,000 -125,037,000
Interest Expense 0 0 0 0
Income Before Tax -103,433,000 -112,020,000 -89,289,000 -105,399,000
Income Tax Expense 0 0 0 -8,876,000
Net Income -103,433,000 -112,020,000 -89,289,000 -96,523,000
Per Share
EPS -1.78 -1.93 -1.55 -1.69
EPS Diluted 0.00 0.00 0.00 0.00
Income Statement (Annual) 2024-12-31 2023-12-31 2022-12-31
Revenue 36,498,000 26,823,000 14,240,000
Cost of Revenue 4,165,000 9,504,000 20,263,000
Gross Profit 32,333,000 17,319,000 -6,023,000
Operating Expenses
R&D Expenses 0 0 0
SG&A Expenses 156,784,000 119,903,000 111,678,000
Operating Expenses 458,070,000 408,806,000 383,024,000
Operating Income -425,737,000 -391,487,000 -389,047,000
Interest Expense 0 0 0
Income Before Tax 717,969,000 -352,088,000 -231,801,000
Income Tax Expense 44,244,000 0 0
Net Income 673,725,000 -352,088,000 -231,801,000
Per Share
EPS 11.86 -6.33 -4.23
EPS Diluted 0.00 0.00 0.00
Balance Sheet (Quarterly) 2024-12-31 2023-12-31 2022-12-31
Assets
Cash and Cash Equivalents 76,247,000 88,205,000 139,259,000
Short Term Investments 817,463,000 688,723,000 643,860,000
Net Receivables 4,109,000 2,810,000 2,206,000
Inventory 27,616,000 19,076,000 8,492,000
Total Current Assets 965,600,000 833,835,000 832,772,000
Property Plant Equipment 54,554,000 69,791,000 88,116,000
Goodwill and Intangibles 0 0 0
Total Assets 1,663,199,000 937,118,000 1,238,718,000
Liabilities
Account Payables 16,643,000 9,780,000 18,616,000
Short Term Debt 16,781,000 15,008,000 13,663,000
Total Current Liabilities 81,156,000 67,955,000 62,629,000
Long Term Debt 40,207,000 56,988,000 0
Total Liabilities 122,243,000 126,099,000 137,904,000
Shareholders Equity
Retained Earnings -148,924,000 -822,649,000 -470,561,000
Total Shareholders Equity 1,540,956,000 811,019,000 1,100,814,000
Balance Sheet (Annual) 2024-12-31 2023-12-31 2022-12-31
Assets
Cash and Cash Equivalents 76,247,000 88,205,000 139,259,000
Short Term Investments 817,463,000 688,723,000 643,860,000
Net Receivables 4,109,000 2,810,000 2,206,000
Inventory 27,616,000 19,076,000 8,492,000
Total Current Assets 965,600,000 833,835,000 832,772,000
Property Plant Equipment 54,554,000 69,791,000 88,116,000
Goodwill and Intangibles 0 0 0
Total Assets 1,663,199,000 937,118,000 1,238,718,000
Liabilities
Account Payables 16,643,000 9,780,000 18,616,000
Short Term Debt 16,781,000 15,008,000 13,663,000
Total Current Liabilities 81,156,000 67,955,000 62,629,000
Long Term Debt 40,207,000 56,988,000 0
Total Liabilities 122,243,000 126,099,000 137,904,000
Shareholders Equity
Retained Earnings -148,924,000 -822,649,000 -470,561,000
Total Shareholders Equity 1,540,956,000 811,019,000 1,100,814,000
Cash Flow Statement (Quarterly) 2024-12-31 2023-12-31 2022-12-31
Operating Activities
Net Income 673,725,000 -352,088,000 -231,801,000
Depreciation & Amortization 5,653,000 6,623,000 18,559,000
Stock Based Compensation 42,847,000 44,766,000 49,296,000
Change in Working Capital -19,768,000 -19,057,000 -16,433,000
Operating Cash Flow -389,841,000 -296,062,000 -309,478,000
Investing Activities
Capital Expenditure -1,685,000 -999,000 -4,881,000
Investments -1,685,000 -999,000 -4,881,000
Investing Cash Flow 363,441,000 239,575,000 243,261,000
Financing Activities
Debt Repayment 0 0 -331,000
Common Stock Issued/Repurchased 14,442,000 5,433,000 2,681,000
Dividends Paid 0 0 0
Financing Cash Flow 14,442,000 5,433,000 2,350,000
Summary
Free Cash Flow -391,526,000 -297,061,000 -314,359,000
Net Change in Cash -11,958,000 -51,054,000 -63,867,000
Cash Flow Statement (Annual) 2024-12-31 2023-12-31 2022-12-31
Operating Activities
Net Income 673,725,000 -352,088,000 -231,801,000
Depreciation & Amortization 5,653,000 6,623,000 18,559,000
Stock Based Compensation 42,847,000 44,766,000 49,296,000
Change in Working Capital -19,768,000 -19,057,000 -16,433,000
Operating Cash Flow -389,841,000 -296,062,000 -309,478,000
Investing Activities
Capital Expenditure -1,685,000 -999,000 -4,881,000
Investments -1,685,000 -999,000 -4,881,000
Investing Cash Flow 363,441,000 239,575,000 243,261,000
Financing Activities
Debt Repayment 0 0 -331,000
Common Stock Issued/Repurchased 14,442,000 5,433,000 2,681,000
Dividends Paid 0 0 0
Financing Cash Flow 14,442,000 5,433,000 2,350,000
Summary
Free Cash Flow -391,526,000 -297,061,000 -314,359,000
Net Change in Cash -11,958,000 -51,054,000 -63,867,000